The National Institutes of Health (NIH) is the nation’s leading medical research agency and the primary Federal agency whose mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability, conducting, supporting and making medical discoveries that improve people’s health and save lives. The National Center for Advancing Translational Sciences (NCATS) is a translational science center that prides itself on its tremendously productive pipeline and is innovative in a number of ways. One of these ways is the development of new Bioactive Small Molecules which can modulate key biological pathways in multiple disease indications.
This bioactive small molecule project is one of the key projects that progresses the study of RR-HNK from a mechanistic and pharmacological perspective. The tritium labeled version of R-ketamine, S-ketamine and RR-HNK will provide key reagents for the study of the pharmacology of all 3 agents.
General description: Labeled R and S Ketamine and 2R,6R-HNK
Specific description: 5 mCi of R and S Ketamine and 2R,6R-HNK to conduct autoradiography work in support of our RR-HNK program.
Period of Performance is within five (5) months from the award of contract.
